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Abstract
Background: To unravel molecular targets involved in glycopeptide resistance, three isogenic strains of Staphylococcus aureus
with different susceptibility levels to vancomycin or teicoplanin were subjected to whole-genome microarray-based
transcription and quantitative proteomic profiling. Quantitative proteomics performed on membrane extracts showed
exquisite inter-experimental reproducibility permitting the identification and relative quantification of >30% of the predicted
S. aureus proteome.
Results: In the absence of antibiotic selection pressure, comparison of stable resistant and susceptible strains revealed 94
differentially expressed genes and 178 proteins. As expected, only partial correlation was obtained between transcriptomic
and proteomic results during stationary-phase. Application of massively parallel methods identified one third of the complete
proteome, a majority of which was only predicted based on genome sequencing, but never identified to date. Several over-
expressed genes represent previously reported targets, while series of genes and proteins possibly involved in the glycopeptide
resistance mechanism were discovered here, including regulators, global regulator attenuator, hyper-mutability factor or
hypothetical proteins. Gene expression of these markers was confirmed in a collection of genetically unrelated strains showing
altered susceptibility to glycopeptides.
Conclusion: Our proteome and transcriptome analyses have been performed during stationary-phase of growth on isogenic
strains showing susceptibility or intermediate level of resistance against glycopeptides. Altered susceptibility had emerged
spontaneously after infection with a sensitive parental strain, thus not selected in vitro. This combined analysis allows the
identification of hundreds of proteins considered, so far as hypothetical protein. In addition, this study provides not only a
global picture of transcription and expression adaptations during a complex antibiotic resistance mechanism but also unravels
potential drug targets or markers that are constitutively expressed by resistant strains regardless of their genetic background,
amenable to be used as diagnostic targets.
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Background
The Gram-positive bacterium Staphylococcus aureus is an
important human pathogen that has become increasingly
resistant to a wide range of antibiotics over the last two
decades. The emergence of multidrug-resistant isolates of
methicillin-resistant  S. aureus (MRSA) exhibiting also
decreased susceptibilities to glycopeptides (glycopeptide-
intermediate S. aureus, GISA) represents a crucial chal-
lenge for antimicrobial therapy, antimicrobial susceptibil-
ity testing, and hospital infection control. After initial
description in Japan of MRSA strains with decreased sus-
ceptibility to glycopeptides [1], clinical isolates showing
similar phenotypes were repeatedly reported in various
countries [2-6]. These strains are distinct from high-level
glycopeptide resistant isolates (VRSA) that result from the
acquisition of the vanA gene from Enterococcus faecalis [7].
Their potential spreading appears of particular concern
since glycopeptides represent the last barrier drugs effec-
tive against MRSA. In addition, intensive use of glycopep-
tides will probably contribute to the selection of other
resistant strains, as already observed for numerous antimi-
crobial agents [8].
Vancomycin is a natural product, isolated from the bacte-
ria Amycolatopsis orientalis in the early fifties [9]. Binding of
this molecule to the N-acyl D-ala-D-ala residue of bacte-
rial peptidoglycan through five strong hydrogen bonds
inhibits cross-linking of the cell-wall [10]. Vancomycin
acts therefore immediately upstream of the transpepti-
dase, the target of β-lactam antibiotics. Structure and
mechanism of action of teicoplanin are similar to that of
vancomycin [10]. Little is known about the underlying
mechanisms which produce GISA strains. A major com-
mon marker of GISA strains is the increased cell-wall
thickness [11]: the prototype GISA strain shows 30–40
cross-linked peptidoglycan layers, whereas fully suscepti-
ble strains contain only 20 layers [12].
Approximately 20% of free D-ala-D-ala residues from the
peptidoglycan structure remain unprocessed by penicil-
lin-binding proteins (PBPs) in vancomycin-susceptible
strains. It was therefore suggested that important quanti-
ties of glycopeptides are trapped by these free residues
[12]. In addition, it was shown that the cross-linking rate
is slower in laboratory-derived GISA compared to suscep-
tible strains [13,14], which may increase the number of
trapped vancomycin molecules and contribute to the
destruction of the mesh-structure of the cell-wall [15].
This cooperative clogging phenomenon has been recently
shown to prevent vancomycin from reaching its target in
the cytoplasmic membrane of strain Mu50, the first clini-
cal isolate reported as GISA [16]. However, analysis of the
digested cell-wall compounds with high-performance liq-
uid chromatography (HPLC) showed different peptidog-
lycan structures among various clinical isolates of GISA
strains showing various cross-linking frequency [17]. In
other backgrounds, originating from in vitro selection of
laboratory strains, structural changes in cell-wall compo-
sition were limited [18] suggesting that there is no single
genetic or biochemical change responsible for the
decreased glycopeptide sensitivity. Several genes were
indeed described to play a role in glycopeptide resistance.
Penicillin-binding protein 4 (PBP4) is hypothesized to
cleave the terminal D-alanine residue from un-cross-
linked peptidoglycan chains [19]. A decrease in PBP4
activity, as observed in clinical isolates of GISA strains,
should therefore result in a higher number of D-ala-D-ala
targets for vancomycin [19]. PBP2 over-expression seems
also correlated with decreased glycopeptide susceptibility
[20,21]. The loss of function of the accessory gene regula-
tor (agr) also increases resistance to glycopeptide [22]. A
recent report demonstrated the contribution of tcaA in the
resistance mechanism. This gene encodes for a transmem-
brane protein showing an intracellular metal-binding
motif and a large extracellular domain of unknown func-
tion. While inactivation of this gene induces increased tol-
erance to glycopeptides, its presence induces
overproduction of the same protein, suggesting that this
protein acts as a sensor and/or as a signal transducer [23].
However, the impact of such an observation on clinical
isolates is still debated [24]. The two-component system
vraRS [25] has been shown to be involved in glycopeptide
resistance. The expression of vraRS  probably mediates
positive regulation of cell-wall synthesis pathway in S.
aureus, through induction of pbp2 [21], thus increasing the
sensitivity of GISA strains to cell-wall synthesis inhibitors
[25]. In another study performed with clinical isolates and
Mu50 or Mu50 derivative strains showing increased levels
of resistance after passages onto vancomycin-containing
medium, most of the genes involved in purine biosynthe-
sis and transport were found up-regulated in the highly
vancomycin-resistant strain as compared to the parental
strain [26]. The deduced hypothesis relies on an increase
in AMP pool able to generate ATP and compensate the dif-
ference in energy requirement observed between suscepti-
ble and resistant isolates.
Altogether, glycopeptide-resistance in Staphylococcus
aureus appears due to multiple factors, including cell-wall
synthesis and processing [27], autolysis [28,29], or regula-
tory events [23,24,30]. A major limitation of this type of
comparative study is the difficulty to obtain isogenic
strains showing various susceptibility phenotypes within
the same genetic background and relevance in the context
of human infections. Our group reported the isolation of
GISA subpopulations emerging from a glycopeptide-sus-
ceptible parental strain in an experimental model of sub-
cutaneous infection [31]. In the same model of infection,
we then isolated a spontaneous revertant strain showing
restored susceptibility to glycopeptides [32]. To improveBMC Genomics 2006, 7:296 http://www.biomedcentral.com/1471-2164/7/296
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our understanding of mechanisms contributing to this
spontaneous evolution, these three isogenic strains pre-
senting different glycopeptide susceptibility levels were
compared at the transcriptome and proteome levels dur-
ing the stationary phase of growth. Transcriptional pro-
files were performed using a customized and extensively
validated oligoarray [33]. In addition, mass spectrometry
(MS)-based protein quantification was performed on
membrane-enriched extracts. Enriched membrane
extracts were chosen for proteomic experiments, since
membrane proteins are often involved in bacterial antibi-
otic resistance and contribute also to numerous important
metabolic pathways and transports, not only of nutrients
but also of chemicals [34-38]. The recently introduced iso-
baric tagging technology was used for simultaneous quan-
tification in all strains [39,40]. Isoelectric focusing (IEF)
on immobilized pH gradients served as the first dimen-
sional peptide separation [41], followed by LC-MS/MS
analysis with a MALDI tandem MS instrument. These
combined approaches performed on isogenic clinical iso-
lates showing stable resistance, without antibiotic pres-
sure revealed genes and proteins identified as potentially
involved in the acquisition of glycopeptide resistance
through the involvement of a complex and multi-factorial
biological network. In addition, most of genes or proteins
previously suspected to contribute to glycopeptide resist-
ance were identified in our study, confirming the robust-
ness of our approach. Finally, six potential targets found
up-regulated at the transcript and protein levels are also
shown to be over-expressed in a collection of S. aureus
clinical isolates from unrelated genetic background show-
ing reduced susceptibility to glycopeptides.
Results
Clonality of the studied strains
MLST performed with partial sequences of 7 genes
revealed that strains MRGR3, 14-4 and 14-4Rev displayed
the same allele profile 2.3.1.1.4.4.3 for arcC, aroE, glpf,
gmk,  pta,  tpi,  yqiL, respectively, corresponding to MLST
239.
To further confirm the clonality of these strains, compar-
ative genome hybridization was performed on an oligoar-
ray covering the whole genome of Staphylococcus aureus
COL, N315, Mu50 and MW2. Additional file 1 illustrates
that susceptible strain MRGR3 and the GISA strain 14-4
displayed strictly identical fluorescence patterns on the
5427 unique oligonucleotide probes [33].
Proteomic experiments
Analysis by 2-DE revealed striking similarities in protein
expression of the two glycopeptide-susceptible strains
(MRGR3 and 14-4Rev). On the opposite, the protein pat-
tern between the glycopeptide intermediate strain (14-4)
and both susceptible strains appeared totally different
(Figure 1). To document this high variability, quantitative
proteomic experiments were performed on membrane-
enriched fractions with MS-based approaches, using iso-
baric tags. Isoelectric focusing of peptides was used as first
dimension separation, prior to LC-MS/MS analysis.
Enrichment was evaluated by assaying the lactate dehy-
drogenase activity, a marker of cytosolic contents. Enzy-
matic activity reached 1330 U/g in total protein extract
and 60 U/g in membrane protein.
All quantitative proteomics experiments were performed
in duplicates. In the first experiment (PR1), 3'724 unique
peptides corresponding to 632 proteins were identified
from the bacterial membrane fraction. In the second
experiment (PR2), 3'719 peptides corresponding to 754
proteins were identified. A total of 551 proteins were com-
monly identified in both experiments. Together, these
experiments yielded a total of 835 unique proteins, cover-
ing approximately 32% of the whole deduced proteome
of S. aureus strain N315 (see Additional files 2, 3, 4).
Among the 2'575 predicted ORFs of strain N315, 637 pro-
tein products (24%) are predicted to be integral mem-
brane proteins (e.g. containing at least one
transmembrane domain). Among the proteins identified
during these two experiments, approximately 20% are
predicted to be integral membrane proteins.
Intense signal from the reporter fragment ions (derived
from the reporter fragment ions abundance at m/z 114.1,
115.1, 116.1 and 117.1 Da) was obtained for almost all
peptides (>95%). Relative quantification could therefore
be performed on all 835 proteins differentially expressed
between strain MRGR3 and 14-4, on 826 proteins
Two windows for each strain are represented to illustrate 2- D gel electrophoresis performed on membrane-enriched  protein fractions of GISA (14-4) and glycopeptide-susceptible  strains (MRGR3 and 14-4Rev) Figure 1
Two windows for each strain are represented to illustrate 2-
D gel electrophoresis performed on membrane-enriched 
protein fractions of GISA (14-4) and glycopeptide-susceptible 
strains (MRGR3 and 14-4Rev). While similar patterns are 
observed between susceptible strains, drastic differences are 
visible when comparing the GISA with either of the suscepti-
ble strains.BMC Genomics 2006, 7:296 http://www.biomedcentral.com/1471-2164/7/296
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expressed between 14-4 and 14-4Rev, and on 826 pro-
teins between MRGR3 and 14-4Rev. A list of these pro-
teins is provided separately (see Additional files 5, 6).
Tables contain the corresponding ORF number, their rel-
ative abundance ratio as well as the coefficient of variation
(CV) of ratios from individual peptides belonging to the
same protein. In average, 4.9 peptides per protein were
used for quantification. As shown in additional tables, the
CV of individual peptide ratios belonging to the same pro-
tein is relatively high. When comparing glycopeptide-sus-
ceptible strains, mean CV value is 23.5%, whereas it
increased to 32.6% between 14-4 and 14-4Rev, and
36.5% between 14-4 and MRGR3. Most identified pep-
tides matched those of the nucleotide sequence-deduced
[42] peptides of strain N315. However, when peptides
were not found in N315 genome, ORF numbers from
other sequenced S. aureus strains are provided in the
tables (see Additional files 5, 6).
Scatter plots of the proteomics ratio revealed very similar
profiles in both glycopeptide-susceptible strains (MRGR3
and 14-4Rev). The number of proteins out of the range -
0.5 to 0.5 (log10 of protein expression ratio) was 0, and
only 10 proteins appeared out of the range of -0.3 to 0.3
(Figure 2A). On the opposite, important modifications of
the distribution were observed between the GISA strain
and any of the 2 glycopeptide-susceptible ones (Figures
2B and 2C). The number of proteins found more abun-
dant in one strain over the other was approximately 60 in
the range of -0.5 to 0.5 and 160 in the range of -0.3 to 0.3,
resulting in a scatter distribution instead of a 0-centered
representation. The lists of identified proteins between the
GISA strain and either of the susceptible strains revealed
almost the same content as all but only 9 proteins were
found in the two analyses, indicating excellent reproduci-
bility of the membrane protein preparations. The experi-
mental variability observed between quantifications of
the two replicates was relatively important. Figures 2B and
2C depict several proteins with divergent expression ratios
between replicates. Due to experimental variation, inher-
ent to quantitative mass spectrometry techniques [43] and
illustrated by the relative high CV values of individual
peptides from the same protein, a conservative approach
was selected that considered only proteins significantly
differentially expressed in both experiments. To this end,
we considered the distribution between both glycopep-
tide-susceptible strains (MRGR3 and 14-4Rev) as a Gaus-
sian normal distribution. Threshold for significant
differential expression was set at the 5th percentile of the
most over- or under-expressed proteins (2.5 percentile
most over-expressed and 2.5 percentile most under-
expressed) between both glycopeptide-susceptible strains
(MRGR3 and 14-4Rev).
A total of 155 proteins are differentially expressed
between strains 14-4 and MRGR3, and 110 proteins
between strains 14-4 and 14-4Rev, which corresponds to
approximately 4% of the deduced proteome. Together,
178 unique proteins are differentially expressed in the
GISA strain. A list of these proteins is given in supplemen-
tary material (see Additional files 5 and 6). Comparison
reveals that more than 65% of these proteins are common
between both lists obtained from comparison of the
resistant strain with either of the two susceptible isolates.
Among these 2 lists, the most important categories
involved proteins playing a role in: energy metabolism,
amino-acids transport, cell envelope biosynthesis, protein
turnover and inorganic ion transport (corresponding to
Dispersion of expression ratios obtained for two independent quantitative proteomic experiments illustrates the reproducibil- ity of the whole procedure and the homogeneity observed when comparing the two susceptible strains (A) Figure 2
Dispersion of expression ratios obtained for two independent quantitative proteomic experiments illustrates the reproducibil-
ity of the whole procedure and the homogeneity observed when comparing the two susceptible strains (A). A good correlation 
but a large difference in protein expression is observed when comparing GISA and either MRGR3 or 14-4Rev (panels B and C 
with correlation coefficients of 0.92 and 0.93; respectively).BMC Genomics 2006, 7:296 http://www.biomedcentral.com/1471-2164/7/296
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COG categories C, E, M, O, P, respectively). Among the 19
categories represented, these 5 categories constituted 40%
of the identified proteins.
Transcriptomic analysis
Genes with statistically significant changes in the level of
expression and differences superior to two-fold changes
were identified and listed for pairwise comparisons (see
additional files 7, 8). According to these criteria, only 10
genes were differentially regulated between strain MRGR3
and 14-4Rev, consisting in 0.4% of the transcriptome.
However, strain 14-4 compared to MRGR3 showed 67 dif-
ferentially regulated genes, whereas 14-4 compared to 14-
4Rev showed 64. In total, 94 differentially expressed genes
were identified between GISA and both glycopeptide-sus-
ceptible strains. Finally, these tables reveal that more than
65% of these genes were common. Among the up- or
down-regulated genes, the most represented transcripts
were found in COG E, K and P corresponding to genes
involved in amino acids transport, transcription and inor-
ganic ions transport, respectively. Thus, 2 out of these 3
categories were also found predominant in the quantita-
tive proteome study.
Correlation between transcriptomic and proteomic data
The transcriptomic expression trends compared to the
proteomic quantification for all identified proteins are
shown in Tables 1 and 2 for the comparison between the
two sensitive strains and the GISA. This analysis reveals
that an equivalent proportion of genes are regulated sim-
ilarly in both comparisons.
The comparison between the proteomic expression direc-
tion (Tables 1 and 2) and the corresponding transcrip-
tomic expression direction according to the functional
classes (according to the COG database) shows important
similarities for most categories. However, two functional
classes (COG O and P, corresponding respectively to post-
translational modification, protein turnover, chaperones
and inorganic ion transport) show opposed quantifica-
tion trends (Figure 3A and 3B).
Finally, strict comparison of significantly differentially
expressed proteins and genes allowed us to identify 7
common ORFs (Tables 3 and 4) showing the same tran-
script and proteins expression trends. Among these genes,
5 are over-expressed whereas only two are under-
expressed. In addition, SA0532 that revealed strongly up-
regulated in microarray experiments was also evaluated in
quantitative analysis.
Genetic relationships between strains showing 
glycopeptide intermediate level of resistance and 
identified markers expression
The expression ratio of the five over-expressed ORFs at the
gene and protein level in glycopeptide-intermediate strain
14-4 as well as the over-expressed transcript SA0532 was
measured on a collection of genetically unrelated strains
(Table 5). Rapid genotype clustering (Figure 4A) shows
that our collection of strains displays at least five distinct
genomic contents confirming that these strains are not
genetically related. Cluster A composed of Mu50 and Mu3
shows some relatedness with NRS17, a strain isolated in
the USA. This relatedness between the two Japanese iso-
lates has been documented previously [44]. Cluster B con-
tains the closely-related French isolates. Patterns C and F
contain only a single isolate (NRS3 and NRS35, respec-
tively). Cluster D confirms that our set of isogenic strains
is unique, and appeared clonal which is in accordance
with the MLST and CGH results (see Additional file 1),
and partially related to cluster E. Finally, the 3 strains
extensively documented in the present study appear
clonal but clearly different from at least 4 other genotypes
identified. As previously documented using pulse-field gel
electrophoresis, our three strains appeared isogenic [45].
Expression levels of the 6 mRNA markers potentially
involved in the mechanism of glycopeptide resistance,
assessed by quantitative PCR using specific oligonucle-
otides (Table 6) is shown on Figure 4B. Important differ-
ences were observed between strains and their genetic
backgrounds. All reference strains (e.g. N315, COL)
showed marginal differences in terms of gene expression
Table 2: Transcriptomic expression direction for the 
differentially expressed proteins between strains 14-4 and 14-
4Rev.
Proteomic
Up = Down
Up 30 12
Transcriptomic = 718
Down 15 31
Table 1: Transcriptomic expression direction for the 
differentially expressed proteins between strains 14-4 and 
MRGR3.
Proteomic
Up = Down
Up 57 12
Transcriptomic = -6 8 4
Down 36 26BMC Genomics 2006, 7:296 http://www.biomedcentral.com/1471-2164/7/296
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Differentially expressed proteins with the corresponding transcripts expression trend regrouped by functions for the compar- ison between GISA strain 14-4, and MRGR3 or 14-4Rev (A and B) Figure 3
Differentially expressed proteins with the corresponding transcripts expression trend regrouped by functions for the compar-
ison between GISA strain 14-4, and MRGR3 or 14-4Rev (A and B). Similar general profiles were obtained for the two compar-
isons between the GISA and either of the susceptible strains while totally different profile was observed for the two 
susceptible strains. Functional classes are: C = energy production and conversion; D = cell division and chromosome partition-
ing; E = amino acid transport and metabolism; F = nucleotide transport and metabolism; G = carbohydrate transport and 
metabolism; H = coenzyme metabolism; I = lipid metabolism; J = translation, ribosomal structure and biogenesis; K = transcrip-
tion; L = DNA replication, recombination and repair; M = cell envelope biogenesis, outer membrane; N = cell motility; O = 
post-translational modification, protein turnover, chaperones; P = inorganic ion transport and metabolism; Q = secondary 
metabolites biosynthesis, transport and catabolism; R = general function prediction; S = function unknown; T = signal transduc-
tion mechanisms; U = secretion; V = defense mechanism. Number of proteins for each category is indicated on top of the cor-
responding columns.BMC Genomics 2006, 7:296 http://www.biomedcentral.com/1471-2164/7/296
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compared to other strains reported as glycopeptides-inter-
mediate. The most variable markers were SA0536.1,
SA1691 and SA0591, which revealed importantly up-reg-
ulated in the vast majority of unrelated GISA strains. A
similar expression pattern of these markers was found in
our resistant strain 14-4 as in the ancestral GISA proto-
type, Mu50 and its clonal derivative Mu3 showing impor-
tant up-regulation of all identified markers. Taken
together, these results illustrate the benefits of performing
combined transcriptomic and proteomic analysis. Indeed,
both were necessary to obtain a global and holistic view of
the state of the bacterial cells. On the opposite, analysis
restricted to gene-expression or protein abundance may
lead to important bias.
Discussion
Technical issues and challenges
The use of isobaric-tagging during isoelectric focusing
prior to LC-MS/MS provided the possibility to quantita-
tively examine a large number of proteins for differential
expression [39,40]. Using membrane-enriched protein
extracts from Staphylococcus aureus during stationary
phase, we consistently identified and quantified relative
protein abundance for approximately 32% of the pro-
teome when comparing pairs of strains. Previously, we
showed that only 23% of the proteome was accessible
using different combinations of protein or peptide frac-
tionation and numerous separation techniques [46]. The
capacity to obtain extended proteome recovery, particu-
larly from membrane fractions, represents one of the
major bottlenecks in proteomic experiments. As expected
from multiple previous reports, numerous soluble con-
taminants are identified from the membrane-enriched
fractions. However, these compounds greatly enhance the
number of identified proteins and contribute to the global
picture of the proteome from a single cellular fraction. In
addition, the removal of important fractions of abundant
cytosolic proteins increases the number of low-abundance
proteins linked to the bacterial membrane [46]. In this
report, we concentrated on membrane-enriched fraction.
Our membrane purification process allowed reducing
drastically the content of cell-wall anchored and cytosolic
proteins, which constitute the most abundant fraction of
cellular proteins by a 200-fold factor. Based on the con-
tent of Staphylococcus aureus proteome, this corresponds to
approximately 4% contamination of membrane fraction
by cytosolic proteins Western blot performed with anti-
bodies raised against S. aureus protein A showed that the
contamination by cell-wall anchored proteins was mar-
ginal. The new approach with an IEF separation of pep-
tides leads to the identification of an appreciable part of
the bacterium proteome, maximizing the chances to dis-
cover new targets involved in S. aureus glycopeptide resist-
ance. In this respect, our analysis of S. aureus proteome
allowed satisfactory representation of low-abundance or
membrane proteins. In this work, 19% of the identified
proteins constituted integral membrane proteins, a value
close to the predicted transmembrane proteome (19.7%
of proteome showed at least 2 putative transmembrane
domains) as deduced from the nucleotide sequence
[42,46]. Numerous examples of bacterial resistance
against different antibiotic families involve membrane
Table 4: List of significantly differentially expressed genes corresponding to over- or under-expressed proteins between 14-4 and 14-
4Rev.
ORF number Function Transcript Protein
SA0022 hypothetical protein, similar to 5'-nucleotidase down down
SA0591 hypothetical protein up up
SA0977 cell surface protein down down
SA1195 peptide methionine sulfoxide reductase regulator MsrR up up
SA1691 similar to penicillin-binding protein 1A/1B up up
SA2113 hypothetical protein up up
SA0591. Shows the VLTHEFGHVL motif, a characteristic of neutral Zn metallo-protease. Membrane associated protein.
SA2113. Shows partial homology with DNA repair protein from Psychrobacter arcticus and is particularly conserved among the different 
Staphylococcus aureus strains (often strictly identical nucleotide sequence).
SA0536.1. 1–19 N-terminal amino-acids are signal peptide (probably exported).
Table 3: List of significantly differentially expressed genes corresponding to over- or under-expressed proteins between 14-4 and 
MRGR3.
ORF number Function Transcript Protein
SA0536.1 vraX up up
SA0591 hypothetical protein up up
SA1195 peptide methionine sulfoxide reductase regulator MsrR up up
SA2113 hypothetical protein up upBMC Genomics 2006, 7:296 http://www.biomedcentral.com/1471-2164/7/296
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proteins [34-37]. Membrane proteins are notoriously dif-
ficult to solubilize during tryptic digestion and, depend-
ing on the number of transmembrane domains, most of
the fractionated peptides remain highly hydrophobic
which is an important limitation during isoelectric focus-
ing [47]. Due to important differences between the three
strains analyzed in this study, this aspect is of utmost
importance. The mean CV of individual peptide ratios
belonging to the same protein varies between 23.5%
(ratios between MRGR3 and 14-4Rev) and 36.5% (ratios
between 14-4 and susceptible strains) which is relatively
low, based on the complexity of the whole experimental
procedure. The sample variability certainly contributed to
these variations, as we observed higher CVs for the com-
parison between susceptible and GISA strains. The high
peptide recovery due to combination of IEF, LC-MS/MS
and labeling strategy is therefore essential for reliable pro-
tein quantification. Similar quantitative profiles were
obtained in each individual experiment, as shown on Fig-
ure 2. However, totally different profiles were observed
between either of the two susceptible strains and the GISA
(Figures 2A and 2B). This observation is concordant with
2D-gel electrophoresis results which clearly illustrates
divergent patterns between GISA and the susceptible
strains.
Whereas high-level glycopeptide resistance in S. aureus
has been shown to rely on the horizontal transfer of vanA
gene from Enterococcus faecalis [7,48], the mechanisms
involved in glycopeptide-intermediate resistance remain
poorly understood and numerous potential mechanisms
are currently explored [11,27]. They probably involve a
complex and global gene expression and protein transla-
tion changes as well as protein processing alterations. The
most documented modifications contributing to this phe-
notype involve profound modifications of cell-wall bio-
synthesis including increased cell-wall thickness, cross-
linking, or accumulation of cell-wall components [11,27].
In this study, several targets involved in cell-wall synthesis
were found differentially expressed either at the protein or
transcript level, or at both levels. Other potential hypoth-
esis rely on the increased abundance of D-Ala-D-Ala resi-
dues, forming false-target trapping glycopeptides or to an
altered regulation of cell-wall synthesis [12,14]. Other
potential mechanisms are related to the requirement of
increased energy synthesis related to larger cell-wall con-
tents, involving phosphoglycerate kinase [49], or purine
metabolism [26].
In a cell, protein abundance is not strictly correlated to
that of its cognate mRNA levels. Thus, a combined tran-
scriptomics and proteomics approach is warranted for
genome-wide identification of molecular targets involved
in the resistance mechanism. Previous experiments per-
formed in our laboratory showed that resistance to glyco-
peptides expressed by strain 14-4 remains stable even after
numerous sub-cultures in antibiotic-free medium [31].
This resistant phenotype relies on constitutive changes in
gene expression and is stable, thus not requiring drug
induction. At stationary phase, a decoupling between pro-
tein and transcripts abundance is generally observed
except for most of constitutive processes [50], supporting
our exploration of the transcriptome and proteome of S.
aureus during this stage.
Table 5: Characteristics of strains subjected to real-time PCR quantification
Strain Name CMI
Vanco Teico Characteristics and origin
NRS 3 4 8 Peritoneal fluid, USA
NRS 11 2 2 Ophthalmologic infection, France
NRS 12 8 8 Ophthalmologic infection, France
NRS 13 4 4 Ophthalmologic infection, France
NRS 14 8 8 Ophthalmologic infection, France
NRS 17 8 8 Bloodstream, USA
NRS 35 2 2 Bloodstream, France
NRS 56 8 8 Wound/skin/soft tissue, Brazil
NRS 63 8 8 Bloodstream, Oman
NRS 64 2 2 Bloodstream, Oman
Mu50 (NRS1) 8 8 Wound/skin/soft tissue, Japan [42]
Mu3 (NRS2) 0.5 2 Purulent sputum, Japan
MRGR3 1 1 Bloodstream, Switzerland
14-4 8 8 Sub-cutaneous infection with MRGR3, Switzerland [31]
14-4Rev 1 1 Sub-cutaneous infection with 14-4, Switzerland [32]
MW2 1 1 Community-acquired Staphylococcus aureus [68]
COL 0.5 1 Ancestor strain of MRSA, England [80]
N315 0.5 1 Pharyngeal smear, Japan [42]BMC Genomics 2006, 7:296 http://www.biomedcentral.com/1471-2164/7/296
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Differentially expressed targets in GISA compared to 
susceptible strains
Proteomics as well as transcriptomics studies revealed
moderate numbers of differentially regulated genes or
proteins. Comparison of GISA strain with either of the 2
susceptible isolates showed a majority of common differ-
entially expressed targets. In addition, a perfect correla-
tion was observed for those common genes in the
transcriptomic evaluation and the proteomic studies.
Genes or gene products known to be involved in different
antibiotic resistance mechanisms, such as PBP2 (SA1283/
Q7A5K8), Ant (SA2385/P04827), MurE (SA0876/
P65480), and the methicillin resistance-related autolysis
protein FmtA (SA0909/Q7A6A2) were over-expressed in
the GISA strain. In addition to these targets involved in
cell-wall biosynthesis, many other proteins involved in
cell-wall metabolism (formation or post-processing and
hydrolysis) were found over-expressed, such as SgtB
(SA1691/Q7A4S6) and SsaA (SA2093/Q7A423). Part of
these compounds involved in cell-wall processing was
reported to alter glycopeptide susceptibility [27]. These
results were shown in gene expression study [27] and are
now confirmed on protein expression levels.
Another important protein target found differentially
expressed at the mRNA and protein levels is the product
of  vraX  gene (SA0536.1/Q99W32, accession number
AB050664). This gene belongs to the vra  operon
(SA0533–SA0535) encoding for genes initially described
to be involved in imipenem resistance. Most of these
genes were up-regulated at the mRNA levels together with
SA0532 and SA0536.1, located upstream and down-
stream of the vra region, respectively and suggesting con-
tribution in glycopeptide resistance. Motive search
revealed that both genes, SA0532 and SA0536 harbored a
putative phosphorylation site, suggesting a role in a regu-
latory process. Regulatory systems contributed to the GISA
phenotype, such as the two-component sensor histidine
kinase, coded by the vraSR genes (SA1701-SA1700), pre-
viously shown as important in the development of resist-
ance to either imipenem or glycopeptides [25]. Our study
reveals also that protein regulators are over-expressed,
such as the signal transduction protein TRAP (Q7A4W3/
SA1653) [51], acting as a signal-transducer protein during
quorum sensing [51,52], the divIVA protein (SA1279/
Q7A5L1) known to regulate cell division, or the putative
transcription factor (SA2296/Q7A3J2) and sarH1, whose
up-regulation is in accordance with a decreased expres-
sion of spa. Finally, the over-expression of proteins
involved in stress protection such as proteinases CtpA
(SA1253/Q7A5M9), MsrA and MsrB (SA1257/P99065
and SA1256/P65446) and the regulator MsrR (SA1195/
Q99Q02), contributing to the reparation of proteins inac-
tivated by oxidation. These attenuators of transcription,
mainly expressed during exponential phase are over-
A. Genotyping of strains evaluated by VNTR Figure 4
A. Genotyping of strains evaluated by VNTR. Based on the 
limit of clonality of the assay (0.1 unit of divergence) [77], 
our collection contains at least 4 unrelated genetic back-
grounds (noted A-D). Control strains whose genome has 
been sequenced have been simultaneously analyzed. B. Gene 
expression of identified markers on a collection of strains 
showing altered susceptibility to glycopeptides. Relative 
expression of 6 gene markers found up-regulated in the 
resistant strain 14-4 compared to the two sensitive strains. 
The same markers were also quantified in a collection of 
strains from the NARSA, selected for their resistance to 
glycopeptide. Values are mean + standard deviation of tripli-
cate measurements from 2 independent experiments. 
Increase expression of selected markers, linked to glycopep-
tide resistance is independent on the background. The com-
plete raw microarray dataset has been posted on the Gene 
Expression Omnibus database [78], accession number 
GSE5188. All additional files are freely accessible [79].BMC Genomics 2006, 7:296 http://www.biomedcentral.com/1471-2164/7/296
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expressed by the GISA strain at the stationary phase and
are also abundant at the protein level. This observation
suggests that the GISA strain is constitutively in a stress
state, despite absence of antibiotic exposure.
Some proteins involved in purine biosynthesis were
found slightly down-regulated in 14-4 compared to sensi-
tive strains at the protein level, whereas none of the genes
involved in this operon was found differentially expressed
by microarray. This observation is in contradiction with a
recent report showing a massive up regulation of the pur
operon [26] in GISA strains isolated in vitro. Our study,
performed on ex vivo derived clinical isolates involves
probably different mechanisms yielding to the resistant
phenotype. These differences illustrate also the impor-
tance of growth conditions and antibiotic resistance selec-
tion. Indeed, these different conditions allow pointing
out complementary mechanisms leading to reduced sus-
ceptibility to glycopeptides. In our comparison, metabolic
targets showing differential expression between GISA and
susceptible strains concerned mainly the metabolism of
arginine. Arginine repressor is up-regulated and conse-
quently argininosuccinate lyase expression is reduced as
observed previously in response to cell-wall active antibi-
otics [53]. The potential effect is the decreased succinate
and fumarate levels and the accumulation of aspartate.
Aspartate is a central compound involved in numerous
metabolic functions such as amino acids synthesis, urea
cycle or energetic transports and cell-wall synthesis.
Another category of targets found differentially regulated
in our study is ABC transporters. Some of these com-
pounds have been proposed as targets for immuno-
therapy [38]. In our study, 4 ABC transporters were found
down-regulated in GISA compared to susceptible strain,
suggesting that the GISA phenotype does not involve this
type of target.
Correlation of proteomic and transcriptomic profiles
In order to compare the transcriptomic profiles with the
proteomic expression ratios, the differentially expressed
proteins were compared to trend of gene-expression ratio
(Tables 1 and 2). A significant part of the over-expressed
proteins corresponds to down-regulated transcripts and
suggests altered protein degradation. Comparison of GISA
with either of the sensitive strains showed similarities
between up- or down-regulated functions between the
transcriptome and the proteome for all functional classes.
However, these tendencies are inverted for the COG func-
Table 6: List and characteristics of primers and probes used for validation of identified markers.
Gene numberA Sequence (5'→3') Length 5'-Dye Concentration (nM)
SA0591
F_SA0591-195F TGGCCGTGCAAAAGATTTAGT 21 200
R_SA0591-275R TGTGTAATTGCGAATCCTTGTTG 23 200
P_SA0591-219T TGTAACAAGTCCACGAGAGCGACAACAGA 29 FAM 100
SA2113
F_SA2113-40F GCCGGTTTAAATGACCGTACTACT 24 200
R_SA2113-117R TTGCAACGCATCACAAAATTG 21 200
P_SA2113-75T CACTTTTGCATAACTTACTTB 20 VIC 100
SA1195
F_SA1195-799F CCTGATTCAGGGATTTTCCAAA 22 200
R_SA1195-877R TTGGCACAGTCAATGACTTAACATC 25 200
P_SA1195-822T TCACCTCGGATGCCAAAACTCAAACCT 27 FAM 100
SA1691
F_SA1691-319F CATCATGGATTCGATTTGAAAGG 23 200
R_SA1691-389R CCTTGCACATCTCTGTCGCTAA 22 200
P_SA1691-344T CAACTAGAGCTTTATTTTCAB 20 FAM 100
SA0536.1
F_SA0536.1-31F GGCGCACCAGTTTATGAAATTAT 23 200
R_SA0536.1-111R TTCAGTATCACTAAATGAATCGTCACAT 28 200
P_SA0536.1-60T AACGTTTCAGCATGTTTB 17 VIC 100
SA0532
F_SA0532-15F GATTGCGATAACTTCTTTTCTCTAT 25 200
R_SA0532-115R AATCAAACTTAAGCCCTAGATAAA 24 200
P_SA0532-51T CAGTATCAAATTTATCTAGGGCTTAB 25 VIC 100
rRNA16S
F_rRNA16s-551F GGCAAGCGTTATCCGGAATT 20 200
R_rRNA16S-651R GTTTCCAATGACCCTCCACG 20 200
P_rRNA16s-573T CCTACGCGCGCTTTACGCCCA 21 FAM 100
A Based on the annotation of N315 genome.
B Minor groove binder (MGB) probes with non-fluorescent quencher bound to the 3'-end (Applied Biosystems).BMC Genomics 2006, 7:296 http://www.biomedcentral.com/1471-2164/7/296
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tions O and P, corresponding to post-translational modi-
fication, protein turnover, chaperones; and inorganic ion
transport and metabolism, respectively. Indeed, most pro-
teins in these functional groups are up-regulated whereas
most transcripts are down-regulated. Similarities are
observed by comparing the glycopeptide intermediate
strain with the two susceptible strains. The analysis
revealed also that most of the expressions have the same
trend in proteomic and in transcriptomic (mainly related
to a reduced metabolism in the GISA) but some regions
showed different directions. These regions are probably
composed of genes showing altered turn-over rates
[50,54], as previously observed [46]. Finally, genes and
proteins found differentially expressed showing the same
trend represent potential targets for rapid diagnostic of
evolution to GISA phenotype. These lists contain
SA0536.1 (vraX), SA0591 and SA2113, two hypothetical
proteins and msrR. Additionally, SA0532 showing an ele-
vated difference in expression between 14-4 and MRGR3
appeared also as a potential marker of interest. The expres-
sion at the mRNA level was evaluated in a collection of
unrelated strains showing altered susceptibility to glyco-
peptides. Among our collection, 5 unrelated genetic back-
grounds were identified and all of them displayed
intermediate level of resistance to glycopeptides. The level
of expression of 6 markers found up-regulated in our in
vivo isolated strain was very similar to that observed in the
ancestral GISA strains. One of these markers, SA0536.1,
has been very recently identified as up-regulated in GISA
strains [30]. In accordance with this report, SA0536.1 was
found up-regulated in all the genetically unrelated strains
of our study. However this study observed that the up-reg-
ulation of SA0536.1 is not related to vancomycin induc-
tion [30] but is constitutive in all our strains. McAleese
suggested as "provocative findings" that the expression of
several markers is constitutive as revealed by our work.
Compared to the different studies published in the field
and elaborating on potential mechanisms involved in
glycopeptide resistance, this study was performed using
GISA strains recovered in the absence of antibiotic pres-
sure. However, most genes previously discovered in differ-
ent GISA strains, either selected in vitro or in vivo, were also
documented in our study. To the involvement of cell-wall
biosynthesis as contributor of the GISA phenotype, our
analysis now adds the discovery of new targets present in
higher abundance in the GISA strains. Our determination
revealed also the contribution of the msr locus, as well as
that of several transporters that could contribute to a more
direct resistance mechanism. In that sense, the presence at
the protein levels of these targets appeared as a strong evi-
dence. Thus, our results suggest that glycopeptide resist-
ance is a stable phenomenon acquired by Staphylococcus
aureus and expressed in the absence of any selection pres-
sure. Finally, coupled to a rapid genotyping method, we
identified markers potentially involved in the resistance
mechanisms, potentially amenable to be used as diagnos-
tic markers.
Conclusion
Combined proteomic and transcriptomic analyses
allowed obtaining a global view of complex processes
involving differentially regulated factors contributing to
antibiotic resistance. This combined information is essen-
tial for the global integration of the data. Several potential
genes and proteins leading to glycopeptide resistance were
identified. This study provides the identity of targets
potentially related to the bacterial evolution toward a
GISA phenotype, thus a contribution to the elucidation of
complex mechanisms leading to glycopeptide resistance.
In view of the results found in the literature and addi-
tional information obtained in this study, we showed that
our genetic background appeared particularly relevant
and that multiple mechanisms are mobilized by Staphylo-
coccus aureus to evolve to the GISA phenotype. In addition,
several markers reflecting the potential evolution of Sta-
phylococcus aureus to the GISA phenotype have been iden-
tified.
Methods
Reagents and chemicals
All chemicals purchased were of the highest purity grade,
unless otherwise stated. MilliQ water (Millipore, Bedford,
MA) was used for the preparation of all buffers and sol-
vents. Methanol, hydrochloric acid, magnesium chloride,
potassium chloride, saccharose were purchased from
Merck (Darmstadt, Germany). Acetonitrile (AcN) was
purchased from Biosolve (Valkenswaard, The Nether-
land). High boiling-point petroleum ether, SDS, ortho-
phosphoric acid and 2,2,2-trifluoroethanol (99.0%) were
purchased from Fluka (Buchs, Switzerland). Trifluoroace-
tic acid (TFA), α-cyano-4-hydroxycinnamic acid, 1,4-
dithioerythritol (DTE), ammonium bicarbonate, potas-
sium chloride, potassium dihydrogenophosphate, iodoa-
cetamide, glycerol, glycine, phosphate buffered saline,
porcine trypsin and Tris were from Sigma-Aldrich (St.
Louis, MO). IPG strips (3–10, nonlinear, 18 cm) were
purchased from GE Healthcare (Piscataway, NJ). Agarose,
ampholines (3–10) and molecular mass markers were
purchased from BioRad (Hercules, CA). Mueller Hinton
broth was obtained from Difco (Detroit, MI), and saccha-
rose from Merck (Darmstadt, Germany). The murolytic
enzyme lysostaphin (Ambicin) was purchased from
Applied Microbiology Inc (Tarrytown, NY). dCTP coupled
to cyanine dyes were obtained from NEN (Perkin Elmer,
Boston, MA, USA).
Strains, growth conditions and time point
MRSA strain MRGR3, a glycopeptide-susceptible strain
was isolated from a patient with catheter-related sepsisBMC Genomics 2006, 7:296 http://www.biomedcentral.com/1471-2164/7/296
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[31]; it is highly pathogenic in a rat model of chronic
infections [55]. Strain 14-4, a stable isogenic GISA strain
was recovered from an experimental infection with
MRGR3 [31]. Strain 14-4Rev that spontaneously emerged
during infection with strain 14-4 is a revertant glycopep-
tide-susceptible isolate [32]. For protein extracts, strains
MRGR3, 14-4 and 14-4Rev were grown with agitation at
37°C in Mueller Hinton Broth (MHB; 200 mL in 1000-
mL flask), as previously described [56]. At stationary
phase (OD540 nm = 6 corresponding to 2–3 × 109 cells/ml),
cells were chilled on ice and harvested by centrifugation at
8'000 × g for 5 min at 4°C. For preparation of crude mem-
brane extracts, 20 mL culture aliquots were washed in 1.1
M saccharose-containing buffer [46], then suspended in 2
mL aliquots of the same buffer containing 50 μg/mL of
the hydrolytic enzyme lysostaphin for 10 min at 37°C.
Protoplasts were recovered after centrifugation (30 min at
8,000 × g) and hypo-osmotic shock was applied in the
presence of 10 μg/mL DNase I (Fluka, Buchs, Switzerland)
to decrease the viscosity of the medium. Crude membrane
pellets were obtained after ultracentrifugation at 50,000 ×
g for 50 min in a Beckman Optima TLX (Beckman Coulter
Intl SA, Nyon, Switzerland).
Evaluation of membrane extracts purity-Evaluation of
membrane enrichment was performed by assaying the lac-
tate dehydrogenase following a previously described
method [57,58] in a LX20 Beckman-Coulter (Beckman
Coulter Intl SA, Nyon, Switzerland). In addition, total and
membrane protein extracts (20 μg) were separated on
SDS-PAGE, transferred to PVDF membrane [59] then
incubated with anti-protein A (clone spa-27, Sigma, at a
1:750 dilution). Anti-mouse IgG coupled to phosphatase
(1:7500 dilution) was used to reveal specific binding. A
large 50 kD smeary band was obtained in total protein
extracts whereas in membrane-enriched fraction, the
staining was close to the limit of detection of the Western
blot procedure (see Additional file 9).
A strain collection showing altered susceptibility levels to
glycopeptides (Table 5) was obtained from the Network
on Antimicrobial Resistance in Staphylococcus aureus
(NARSA, Virginia, USA) [60].
Proteomics experiments
Two-dimensional gel electrophoresis was performed
using previously described conditions [47]. Quantitative-
MS based proteomic experiments were performed in
duplicates, on two individual cultures. For each experi-
ment, an estimated amount of 300 μg of crude membrane
protein extract (BCA method, Pierce, Rockford, IL) from
each strain was separately dissolved, reduced, alkylated,
digested and labeled with iTRAQ compounds according
to the manufacturer's procedure (Applied Biosystems,
Framingham MD). For the first proteomic experiment
(PR1), strain MRGR3 was labeled with iTRAQ 114, strain
14-4 with iTRAQ 116 and 14-4Rev with iTRAQ 117. For
the second proteomic replicate experiment (PR2), strain
MRGR3 was labeled with iTRAQ 117, strain 14-4 with
iTRAQ 114 and 14-4Rev with iTRAQ 115. After mixing,
peptides from all strains were concentrated and desalted
using an Oasis HLB 1 cc 10 mg solid-phase extraction car-
tridge (Waters, Milford, MA). Desalted peptides were re-
suspended in 300 μl isoelectric focusing buffer containing
4 M urea and 0.5% ampholines in 50% TFE. The IPG
strips were rehydrated overnight with the peptide solu-
tion. Isoelectric focusing was performed with the follow-
ing conditions: Linear gradient from 0 to 3'500 V in 3
hours, and 3'500 V during 20 hours. After isoelectric
focusing, the IPG strip was washed 3 times 10 seconds in
3 distinct baths containing high boiling point petroleum
ether in order to remove the paraffin oil. The strip was
then manually cut in 58 (PR1) and 64 (PR2) fractions
with a scalpel, and gel pieces were placed in polypropyl-
ene tubes containing 70 μl 0.1% TFA. After 30 minutes,
TFA solution was transferred into another tube and
replaced with 0.1% TFA in 50% Acetonitrile (AcN). After
30 minutes, the solution was also transferred to the sec-
ond tube and replaced with 0.1% TFA in AcN, also trans-
ferred after 30 minutes. The combined solution was then
dry-evaporated, re-suspended in 25 μl HPLC buffer A
(0.1% formic acid in 5% AcN) and stored at -20°C. A vol-
ume of 5 μl of peptide solution of each fraction was
loaded on a 10 cm long home-made column with an ID
of 100 μm, packed with C 18 reverse phase (YMS-ODS-
AQ200, Michrom BioResource, Auburn, CA), and eluted
directly on a MALDI target using a home-made spotting
robot. The elution gradient ranged from 4% to 38% sol-
vent B (0.1% formic acid in 80% AcN) in 40 minutes. Pep-
tides were analyzed in MS and MS/MS mode using a 4700
MALDI-TOF/TOF tandem mass spectrometer (Applied
Biosystems, Framingham, MA).
After MS/MS analysis, peak lists from each fraction were
created with embedded software (4700 explorer 2.0 peak-
to-mascot) and merged together before database search-
ing using the Phenyx platform from GeneBio (Geneva,
Switzerland). Searching was performed against a home-
made database containing all predicted ORFs from
genome-sequenced strain N315 [42] and proteins from
other S. aureus and S. epidermidis strains with less than
90% identity (5515 entries extracted from UniProt
(release 46, 25 Jan. 2005) and TrEMBL (release 29, 25 Jan.
2005)). Multiple-peptide hits were accepted with individ-
ual peptide z-score higher than 6, single-peptide hits with
z-scores higher than 8, corresponding to a predicted pep-
tide false-positive ratio of respectively less than 6% and
3.5%. These values were obtained after plotting false pos-
itive rates against true positive rates on a ROC-like curve.
False positive hits where obtained from searches in theBMC Genomics 2006, 7:296 http://www.biomedcentral.com/1471-2164/7/296
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entire SwissProt TrEMBL database without species restric-
tion and true positive were selected from validated, high-
score peptides matching to S. aureus entries.
Areas of the iTRAQ reporter ions for each peptide were
extracted with Phenyx software. Peptides with highest
iTRAQ reporter fragment ion areas below 2000 (arbitrary
unit from "peak to mascot" software) were excluded.
Mean peptide expression ratio was mathematically cen-
tered on value 1. Before prediction of transmembrane
(TM) segments, the signal peptide of the predicted protein
sequences was removed using the SignalP V2.0 tool [61],
accessible through the internet [62]. The number of TM
segments was then predicted using the TMHMM2.0 tool
[63], also accessible through the internet [64]. Functional
classes of all predicted ORFs were retrieved from the COG
database [65,66], publicly available from the internet
[67].
Microarray manufacturing
The microarray was manufactured by in situ synthesis of
8'454 long oligonucleotide probes (Agilent, Palo Alto,
CA, USA), selected as previously described [33]. It covers
>99% of all ORFs annotated in strains N315, Mu50 [42],
MW2 [68] and COL [69]. Briefly, the microarray contains
8'192 S. aureus specific oligonucleotides. Based on availa-
ble sequence information 89% of the probes are common
to the 4 strains used for the design, whereas 11% are
strain-specific capture elements. Extensive experimental
validation of this array has been described previously,
using CGH, mapping of deletion and quantitative RT-PCR
[33].
Preparation of labeled nucleic acids
S. aureus strains were grown overnight in MHB, as
described for proteomics analysis. Total RNA was
extracted from 2 mL of cells at 2–3 × 109 cells/ml, using
the RNeasy kit (Qiagen, Basel, Switzerland), as previously
described [32,33]. After additional DNase treatment, the
absence of remaining DNA traces was evaluated by quan-
titative PCR (SDS 7700; Applied Biosystems, Framing-
ham, MA) with assays specific for 16s rRNA and the HU
genes [32,70], encoding for a DNA-binding protein.
Batches of 10 μg total S. aureus RNA were labeled by Cy-3
dCTP using the SuperScript II (Invitrogen, Basel, Switzer-
land) following manufacturer's instructions. Labeled was
then purified onto QiaQuick columns (Qiagen). Purified
genomic DNA from the 4 sequenced strains was extracted
(DNeasy, Qiagen), labeled with Cy-5 dCTP using the Kle-
now fragment of DNA polymerase I (BioPrime, Invitro-
gen, Carlsbad, CA) [33,71].
Hybridization and scanning parameters
Cy5-labeled DNA (0.125 μg per stain) and Cy3-labeled
cDNA (10 μg) mixture was diluted in 250 μl Agilent
hybridization buffer, and hybridized at a temperature of
60°C for 17 hours in a dedicated hybridization oven
(Robbins Scientific, Sunnyvale, CA, USA). Slides were
washed, dried under nitrogen flow, and scanned (Agilent,
Palo Alto, CA, USA) using 100% PMT power for both
wavelengths. Data were extracted and processed using
Feature Extraction™ software (version 6.1.1, Agilent). For
expression analysis, local background-subtracted signals
were corrected for unequal dye incorporation or unequal
load of labeled product. The algorithm consisted of a rank
consistency filter and a curve fit using the default LOWESS
(locally weighted linear regression) method. Data consist-
ing of three independent biological experiments were
expressed as Log10 ratios and analyzed using GeneSpring
7.0 (SiliconGenetics, Redwood City, CA, USA). Statistical
significance of differentially expressed genes was identi-
fied by variance analysis (ANOVA) [72], performed using
GeneSpring, including the Benjamini and Hochberg false
discovery rate correction (5%).
Real-time PCR validation of discovered markers
Gene-specific probes were designed using Primer Express
2.0 (Applied Biosystems). Oligonucleotide primers and
probes (Table 6) obtained from Eurogentec (Seraing, Bel-
gium) or Applied Biosystems (minor groove binder cou-
pled to dark quencher) were solubilized in water and
reactions were assembled in a one-step RT-PCR enzymatic
mixture (Invitrogen) in a final volume of 15 μl. Reaction
was performed in a SDS 7500 (Applied Biosystems). All
measurements were performed in triplicate from two
independent samples of purified RNA (0.5 ng/reaction)
obtained from overnight and log-phase cultures isolated
as previously described [33,73]. Cycle thresholds were
assessed using default parameters. Briefly, the standard
deviation of fluorescent values recorded from cycles 3–15
was multiplied by 10 to define the cycle threshold line.
Cycle thresholds (Ct) were then derived from the intercept
between this line and the signal obtained during the RT-
PCR reaction. Results were normalized using intensity lev-
els recorded for the rRNA 16s gene as previously described
[32]. Figure shows relative gene expression for all strains
as compared to 14-4Rev.
Genotyping of the related strains – Multi-locus Sequence
Typing (MLST) was performed using previously described
procedure and primers [74]. Allele numbers were assigned
according to MLST Web site [75]. Comparative genome
hybridization was performed according to the previously
described procedure [76].
Genotyping of Staphylococcus aureus collection by a 
variable number of tandem repeat (VNTR) approach
A previously published method was used to evaluate the
genomic content of strains composing the analyzed col-
lection [76,77]. Briefly, this assay is based on a multiplexBMC Genomics 2006, 7:296 http://www.biomedcentral.com/1471-2164/7/296
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PCR using ten primer pairs targeting genes showing varia-
ble number of tandem repeats. This method shows at least
similar discriminatory power as that of pulse field-gel
electrophoresis [77]. In addition to the NARSA collection,
fully sequenced control strains were subjected to the
assay.
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